Pluri Inc. (PLUR) Form 8-K — Oct 30, 2026
Pluri Inc. entered a Partnership Agreement with ZEO ScientifiX under which Pluri will grant ZEO an exclusive license to manufacture and commercialize its regenerative medicine portfolio in the United States. At closing, Pluri will hold 50% of ZEO's shares, control 4 of 7 board seats, and receive Series D Preferred Shares carrying 51% of votes, plus warrants for up to 7.5% more equity at $4.00-$5.50 per share. Separately, Pluri agreed to sell 909,092 shares at $1.10 plus 100%-coverage warrants at $1.30 to two purchasers for gross proceeds of $1.0 million, closing on or before October 30, 2026, for corporate development and working capital.
Key figures
- Debt Amount
- 27500000
- Interest Rate
- 4
- Maturity Date
- 2026-06-01
- Gross Proceeds
- 1000000
- Offering Price
- 1.1
- Shares Offered
- 909092
- Max royalty rate
- 7.0%
- Closing deadline days
- 90
- Eib first tranche eur
- 20000000
- Pipe warrant coverage
- 100%
- Zeo warrant 1 coverage
- 5%
- Zeo warrant 2 coverage
- 2.5%
- Eib total commitment eur
- 50000000
- Zeo warrant 1 strike usd
- 4
- Zeo warrant 2 strike usd
- 5.5
- Initial zeo share issuance
- 41%
- Pluri board nominees at zeo
- 4 of 7
- Tranche b milestone price usd
- 5.5
- Pluri zeo ownership at closing
- 50%
- Pipe warrant exercise price usd
- 1.3
- Pipe subscription per purchaser usd
- 500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.